Lung Volume Reduction Surgery Denied by Insurance? How to Appeal

For patients with severe emphysema who have exhausted medical management, lung volume reduction surgery (LVRS) and endobronchial valve (EBV) placement are established procedures that can meaningfully improve lung function, exercise capacity, and quality of life. Both are covered under Medicare and many commercial plans — but both are subject to strict eligibility criteria that create frequent denials. Here is how to appeal.

What Is Lung Volume Reduction?

Emphysema destroys lung tissue and causes hyperinflation — the lungs become overinflated with trapped air, mechanically disadvantaging the diaphragm and impairing breathing. Lung volume reduction removes or blocks the most destroyed portions of the lung, allowing healthier tissue to expand and the diaphragm to function more efficiently.

Lung Volume Reduction Surgery (LVRS) is an open surgical procedure (typically video-assisted thoracoscopic surgery, VATS) that removes 20-30% of the most destroyed lung tissue from each side. It was validated by the National Emphysema Treatment Trial (NETT), a large NIH-funded randomized controlled trial published in 2003.

Endobronchial valves (EBV) are a less invasive bronchoscopic alternative. One-way valves are placed in the airways supplying the most diseased lung segments, causing them to collapse (atelectasis). The Zephyr valve is the first EBV system approved by the FDA in the United States (2018). EBV therapy requires absence of collateral ventilation — the target lobe must be isolated from adjacent lobes — typically confirmed by Chartis assessment or high-resolution CT fissure analysis.

Medicare Coverage Criteria for LVRS

Medicare has established specific criteria for LVRS coverage based on the NETT trial data. To qualify, a patient must:

• Have a primary diagnosis of severe emphysema (predominantly upper-lobe distribution is associated with best outcomes)
• Have an FEV1 between 20% and 45% predicted
• Have a total lung capacity (TLC) greater than or equal to 100% predicted
• Have a residual volume (RV) greater than or equal to 150% predicted
• Have a PaCO2 at or below 60 mmHg on room air (at rest)
• Have a PaO2 at or above 45 mmHg on room air (at rest)
• Have completed a course of pulmonary rehabilitation and participated at least 16 sessions

Medicare explicitly excludes patients with predominantly non-upper-lobe emphysema and high post-rehabilitation exercise capacity (as defined by the NETT protocol), as these patients had worse outcomes with LVRS in the trial.

For EBV placement, Medicare coverage requires documentation of target lobe heterogeneity and absence of collateral ventilation.

Why Insurers Deny LVRS and EBV

Criteria not met on paper. Even when a patient clinically qualifies, the documentation submitted for Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization may not clearly demonstrate each criterion. An FEV1 measured at a different time point, a missing TLC or RV measurement, or an incomplete pulmonary rehabilitation record can sink an authorization request.

Non-upper-lobe distribution denial. If imaging shows predominantly lower-lobe or diffuse emphysema rather than upper-lobe predominant disease, the insurer may deny citing the NETT trial exclusion. This can be challenged if the treating physician can document the basis for the clinical decision — some patients with heterogeneous non-upper-lobe disease have benefited from LVRS in real-world practice.

EBV denied as "experimental." Although the Zephyr valve is FDA-approved, some plans still classify EBV placement as investigational. This position is increasingly difficult to defend given the level of clinical evidence and FDA approval status, and should be challenged directly in the appeal.

Pulmonary rehabilitation not completed. Medicare requires completion of PR before LVRS. If the patient has not yet completed the required sessions, the authorization will be denied until PR is finished and documented.

High surgical risk exclusion. Patients with very poor baseline function (FEV1 below 20% with either homogeneous emphysema or DLCO below 20% predicted) were found to have high surgical mortality in the NETT trial. Some insurers apply this exclusion broadly. Your thoracic surgeon's risk-benefit assessment is important documentation if you fall in a borderline zone.

Building Your Appeal

Your appeal package should be thorough and match the criteria in the insurer's coverage policy:

• High-resolution CT chest with radiologist report describing distribution of emphysema (upper-lobe, lower-lobe, or heterogeneous)
• Full PFT panel: FEV1 (% predicted), TLC, RV, DLCO
• ABG results on room air
• Six-minute walk distance (pre- and post-pulmonary rehabilitation)
• Pulmonary rehabilitation completion certificate with session dates
• Thoracic surgeon's operative recommendation with clinical rationale
• Pulmonologist's clinical notes documenting maximal medical therapy and ongoing symptom burden
• For EBV: Chartis catheter assessment results or CT fissure analysis confirming absence of collateral ventilation
• ICD-10 codes: J43.1 (panlobular emphysema), J43.2 (centrilobular emphysema), J43.9 (emphysema, unspecified)

Addressing the Experimental Claim for EBV

If your insurer is denying EBV on experimental grounds, your appeal should cite:

• FDA approval of the Zephyr valve (June 2018)
• The LIBERATE trial (published in NEJM), which demonstrated significant FEV1 improvement at 12 months
• CMS National Coverage Determination language and any applicable Medicare contractor local coverage determinations

Your interventional pulmonologist can provide a letter summarizing the clinical evidence and explaining why EBV is the appropriate approach for your specific anatomy.

Escalation Path

If the internal appeal is denied, request external independent review. LVRS and EBV cases where the patient genuinely meets coverage criteria tend to succeed with external reviewers who have thoracic surgery or pulmonology expertise. Provide the external reviewer with the same complete documentation package and a clear summary of how your case meets each criterion.

A denial for lung volume reduction is worth fighting. Start your appeal at claimback.app/appeal to get a personalized appeal strategy based on the specific reason your claim was denied.

Related Reading

• Lung Cancer Treatment Insurance Denied? How to Appeal
• Lung Transplant Insurance Claim Denied? How to Appeal
• 5 Reasons Insurance Companies Deny Claims (And How to Fight Back)
• Abdominoplasty Insurance Claim Denied? How to Appeal (Medical Necessity)
• Abortion Insurance Coverage Denied? How to Appeal